[Opmerking] Remming van interleukines 17A en 17F bij artritis psoriatica

[Opmerking] Remming van interleukines 17A en 17F bij artritis psoriatica

februari 16, 2020 0 Door admin

Translating…


CBD Olie kan helpen bij artrose. Lees hoe op MHBioShop.com


Huile de CBD peut aider avec l’arthrose. Visite HuileCBD.be


 

Psoriasis is the most common chronic inflammatory skin disease; 15–30% of patients with psoriasis have psoriatic arthritis.

  • Alinaghi F
  • Calov M
  • Kristensen LE
  • et al.

Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies.

The interleukin (IL) 23 and IL17 pathway has a crucial role in pathogenesis, and inhibitors of the IL17 pathway have rewritten treatment paradigms especially for psoriasis control, with up to 50% of patients achieving at least 100% reductions in Psoriasis Area and Severity Index (PASI) scores (PASI100).

  • Blauvelt A
  • Chiricozzi A

The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis.

Before IL17 inhibitors were introduced, around 60% of patients achieving a 75% reduction in PASI scores was the best outcome that could be expected.

To read this article in full you will need to make a payment

References

  1. 1.
    • Alinaghi F
    • Calov M
    • Kristensen LE
    • et al.

    Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies.

    J Am Acad Dermatol. 2019; 80: 251-265

  2. 2.
    • Blauvelt A
    • Chiricozzi A

    The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis.

    Clin Rev Allergy Immunol. 2018; 55: 379-390

  3. 3.
    • Reis J
    • Vender R
    • Torres T

    Bimekizumab: the first dual inhibitor of Interkeukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis.

    Biodrugs. 2019; 33: 391-399

  4. 4.
    • Sakkas L
    • Zafiriou E
    • Bogdanos D

    mini review: new treatments in psoriatic arthritis. focus on the IL-23/17 axis.

    Front Pharmacol. 2019; 10: 872

  5. 5.
    • Glatt S
    • Helmer E
    • Haier B
    • et al.

    First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

    Br J Clin Pharmacol. 2017; 83: 991-1001

  6. 6.
    • Glatt S
    • Baeten D
    • Baker T
    • et al.

    Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

    Ann Rheum Dis. 2018; 77: 523-532

  7. 7.
    • Ritchlin CT
    • Kavanaugh A
    • Merola JF
    • et al.

    Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.

    Lancet. 2020; 395: 427-440

  8. 8.
    • Papp KA
    • Merola JF
    • Gottlieb AB
    • et al.

    Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

    J Am Acad Dermatol. 2018; 79: 277-286

Article Info

Publication History

Published: 08 February 2020

Identification

DOI: https://doi.org/10.1016/S0140-6736(20)30220-8

Copyright

© 2020 Elsevier Ltd. All rights reserved.

ScienceDirect

Access this article on ScienceDirect

Lees Meer